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Abstract 
The etiology of Autism Spectrum Disorders (ASDs) remains largely unknown. Identifying 
vulnerability genes for autism represents a major challenge in the field, and allows the 
development of animal models for translational research. Mice lacking the mu opioid receptor 
gene (Oprm1
-/-
) were recently proposed as a monogenic mouse model of autism, based on 
severe deficits in social behavior and communication skills. We confirm this hypothesis by 
showing that adult Oprm1
-/-
 animals recapitulate core and multiple comorbid behavioral 
symptoms of autism, and also display anatomical, neurochemical and genetic landmarks of 
the disease. Chronic facilitation of mGluR4 signaling, which we identified as a novel 
pharmacological target in ASDs in these mice, was more efficient in alleviating behavioral 
deficits than the reference molecule risperidone. Altogether, our data provide first evidence 
that disrupted mu opioid receptor signalling is sufficient to trigger a comprehensive autistic 
syndrome, maybe through blunted social reward processes, and this mouse model opens 
promising avenues for therapeutic innovation. 
 
Introduction 
Autism Spectrum Disorders (ASDs) are complex neurodevelopmental diseases with 
high heterogeneity and heritability, whose diagnosis is based on two types of behavioral 
symptoms: impaired social reciprocity and communication, and restricted range of behaviors, 
interests and activities (DSM-5). Secondary - comorbid - symptoms vary substantially, and 
include anxiety disorders, cognitive and motor deficits, aggressive behavior and epileptic 
episodes (Johnson and Myers 2007; Mazurek et al. 2013; Pouw et al. 2013; Robinson 2012; 
Veenstra-VanderWeele and Blakely 2012; White et al. 2012; Whyatt and Craig 2013). 
Heterogeneity in ASDs points toward multiple primary causes, with genetic factors playing a 
critical role. Large scale genetic studies in patients and preclinical work using animal models 
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have indeed identified over 280 candidate vulnerability genes for ASD (SFARIgene
2.0
 
database, https://gene.sfari.org/autdb/Welcome.do) (Buxbaum et al. 2012; Delorme et al. 
2013; Ecker et al. 2012a; State and Levitt 2011), and suggest that altered synaptic function 
and disrupted excitation-inhibition balance contribute to the pathology. Neuroimaging studies 
have confirmed atypical brain connectivity in ASD patients (Ecker et al. 2012b; Just et al. 
2012). The precise cause of these troubles, however, remains largely unknown.  
Given the high homology between mouse and human genomes and feasibility of 
genetic modifications in mice, interest in developing genetic mouse models of ASDs has 
raised recently, together with the development of dedicated behavioral assessment (Buxbaum 
et al. 2012; Crawley 2007; Robertson and Feng 2011). These models ought to demonstrate 
face (similarity with clinical symptoms), construct (similarity in causal mechanisms) and 
predictive (similarity in response to therapeutics) validity; none of the currently available 
ASD models, however, fully matches such criteria. Nevertheless, they have contributed to a 
better understanding of the neurobiological substrates of autism and to the identification of 
novel promising therapeutic trails. 
Recently, mice lacking the mu opioid receptor gene (Oprm1
-/-
) were proposed as a 
monogenic model of autism (Oddi et al. 2013). These animals indeed demonstrate major 
deficits in social behavior: reduced maternal attachment in mouse pups (Moles et al. 2004), 
altered social reward in juvenile mice (Cinque et al. 2012) and blunted response to female 
vocalizations in adult males (Wohr et al. 2011). Thus, animal research highlights the critical 
role of mu opioid receptors in social responses, and pharmacological effects of mu opioid 
drugs in social play and adult attachment have been shown in rodents (Burkett et al. 2011; 
Trezza et al. 2011). In humans, neural sensitivity to social rejection (Way et al. 2009) and 
social hedonic capacity (Troisi et al. 2011) show significant association with a common 
variant (A118G) of the mu opioid receptor gene (Oprm1), suggesting a role of this receptor in 
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modulating social reward. Consistent with this, social acceptance activates mu opioid 
receptors in the ventral striatum, activation of which predicting the desire for social 
interaction (Hsu et al. 2013). Finally, genetic studies have detected discrete invalidating 
mutations of the Oprm1 gene in ASD patients (SFARIgene
2.0
 database), indicating that such 
invalidation may be sufficient to trigger an autistic syndrome, and providing construct validity 
for the Oprm1
-/-
 mouse model. Whether the absence of mu opioid receptor signaling could 
lead to a comprehensive autistic-like phenotype in the adult animal, however, has not been 
tested yet. Here, we assessed behavioral, neurochemical, anatomical and genetic features of 
ASDs in these animals and, based on gene expression analysis, identified an entirely novel 
pharmacological target for therapeutic intervention in this pathology. 
 
Material and Methods 
Subjects  
Male and female Oprm1
+/+
 and Oprm1
-/-
 mice (Matthes et al. 1996) aged 6-8-weeks were 
bred in-house on an identical hybrid background: 50% 129SVPas - 50% C57BL/6J. For the 
purpose of the present study, Oprm1
+/+
 and Oprm1
-/-
 pups were nurtured by Oprm1
+/+
 and 
Oprm1
-/-
 parents, respectively, except for cross-fostering experiment. Except otherwise stated, 
animals were group housed and maintained on a 12hr light/dark cycle (lights on at 7:00 AM) 
at controlled temperature (21±1°C); food and water were available ad libitum. Experiments 
were analyzed blind to genotypes. Experimental procedures were reviewed and approved by 
the Comité Régional d’Ethique en Matière d’Expérimentation Animale de Strasbourg 
(CREMEAS, 2003-10-08-[1]-58). 
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Behavioral experiments 
Detailed behavioral protocols are described in Supplementary Material and Methods. Social 
abilities were explored using the direct social interaction, the three-chamber and the nest 
building tests; aggressiveness was evaluated using the resident-intruder test. Stereotyped 
behavior was assessed by scoring motor stereotypies and measuring spontaneous alternation 
in a Y-maze. Anxiety-like behavior was evaluated in the marble burying and novelty-
suppressed feeding tests. Motor function was assessed using the string and grip tests, skill 
motor learning task and foot print analysis. Sensitivity to seizures was assessed by scoring 
penthylene tetrazole-induced convulsions. Experiments were performed on separate cohorts 
of naïve animals (Figures 1 and 2), except for tests exploring motor function (string test, grip 
test, accelerating rotarod, foot print analysis, in this order), cross-fostering experiment (Figure 
S3) and pharmacological experiments (Figures 4 and 5), where behavioral testing was 
performed in a battery (time lines in Figures S3a and S5a,b). Equivalent numbers of male and 
female animals were used in each experiment, except for the resident/intruder test, performed 
only in males.  
 
Real-time quantitative PCR analysis  
Brains were removed and placed into a brain matrix (ASI Instruments, Warren, MI, USA). 
CPu, NAc, CeA and VTA were punched out from 1mm-thick slices. Prefrontal cortex (PFC) 
and MeA were dissected from two consecutive slices. Tissues were immediately frozen on 
dry ice and kept at -80°C until use. When assessing transcript levels of a collection of genes 
of interest, we pooled tissue from one male and one female mouse (n=5 samples/genotype) 
for each brain structure and each genotype, as no significant effect of gender was detected on 
mutant phenotype. When assessing transcription of immediate early genes C-fos and Egr1 
after social interaction, we processed each sample individually to parallel individual 
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behavioral data (n=7-8 samples/genotype and treatment). RNA was extracted and purified 
using the MIRNeasy mini-kit (Qiagen, Courtaboeuf, France). cDNA was synthetized using 
the first-strand Superscript II kit (Invitrogen®, Life Technologies, Saint Thomas, France). 
qRT-PCR was performed as previously described (Le Merrer et al. 2013). Primer sequences 
are displayed in Table S1. 
 
Drugs 
 
Pentylenetetrazole (PTZ, Sigma-Aldrich, Saint-Quentin, France) was administered once a 
week at escalating doses (vehicle, 25, 37.5, 50 mg/kg i.p.). Scoring was performed 
immediately after treatment. Risperidone (Sigma-Aldrich, Saint-Quentin, France) at 0.2mg/kg 
i.p. (Penagarikano et al. 2011) was administered 60 min prior testing. VU0155041 (Tocris, 
Bristol, UK) at 5mg/kg i.p. (Duvoisin et al. 2011) was injected 120 min before testing. When 
risperidone and VU0155041 effects were compared to the same vehicle-treated group, control 
animals were tested 60 min after vehicle injection. All compounds were administered in a 
volume of 10ml/kg; vehicle was NaCl 0.9 %. 
 
Statistical analyses 
Statistical analyses were performed using Statistica 9.0 software (StatSoft, Maisons-Alfort, 
France). For all comparisons, values of p<0.05 were considered as significant. Statistical 
significance in behavioral, immunohistochemical, electron microscopy and monoamine 
concentration experiments was assessed using two to four-way analysis of variance 
(genotype, treatment, trial and session effects) followed by Newman-Keules post-hoc test, 
except for nesting and convulsion scores, which significance was tested using the non-
parametric Kruskal-Wallis’ analysis of variance. A standard principal component analysis 
(PCA) (Le Merrer et al. 2012) was performed on behavioral and Fos count data. Loadings for 
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each extracted principal component (PC) are quoted in Table S3. We considered the two first 
extracted PCs (PC1 and PC2) for schematic representation. Significance of qRT-PCR results 
was assessed after transformation using a one-sample t-test, as previously described. 
Unsupervised clustering analysis was performed on the median of transformed qPCR data 
using complete linkage with correlation distance (Pearson correlation) for genes and brain 
region (Cluster 3.0 and Treeview software). 
Detailed protocols for Fos immunohistochemistry, electron microscopy and biogenic amines 
dosage are described in Supplementary Material and Methods. 
 
Results 
Oprm1
-/-
 mice recapitulate core symptoms of autism 
Deficient social interactions are the most remarkable core symptom of autism in humans. We 
assessed social abilities in Oprm1
-/-
 mice using four tests. In the direct social interaction test, 
Oprm1
-/-
 mice spent less time in close interaction with a naive wild-type (WT) conspecific 
compared to Oprm1
+/+
 controls, due to lower frequency and shorter duration of nose and paw 
contacts. Similarly, the frequency of followings was reduced in mutants. In contrast, these 
mice self-groomed more often, particularly after social contact, and for longer than controls, 
without other detectable motor stereotypies (Figures 1a and S1a, statistics in Table S2). In the 
three-chamber test, Oprm1
+/+
 but not Oprm1
-/-
 animals spent more time in nose contact with a 
conspecific versus a toy mouse during the interaction phase. When the toy mouse was 
replaced by a novel conspecific (recognition phase), Oprm1
+/+
 but not Oprm1
-/-
 mice spent 
more time interacting with this unfamiliar animal (Figures 1b and S1b, Table S2). Defective 
recognition of a novel social partner did not result from general alteration of recognition 
abilities, as object recognition was preserved in mutant animals (Figure S1c), or from 
deficient olfactory perception, as shown in previous studies (Cinque et al. 2012; Moles et al. 

Figure 1. Oprm1
-/-
 mice show core symptoms of autism. (a) In the direct social interaction 
test, Oprm1
-/-
 animals show decreased time in close social contact, due to lower frequency and 
duration of nose and paw contacts. Following was decreased whereas self-grooming, 
especially after social contact, was increased in mutants (n=8 per genotype). (b) In the three-
chamber task, WT controls but not Oprm1
-/-
 mice spend more time interacting with a mouse 
rather than a toy (interaction phase), or a novel rather than a familiar conspecific (recognition 
phase) (n=13-14 per genotype). (c) Male Oprm1
-/-
 animals are more aggressive in the 
resident-intruder test, with increased numbers of attacks and episodes of ptosis (n=8 per 
genotype). (d) Oprm1
-/-
 mice show impaired ability to build a nest (n=8 per genotype). (e) 
Oprm1
-/-
 mice display motor stereotypies, with increased rearing, grooming, circling and head 
shakes (n=8 per genotype). (f) Mutant mice show deficient patterns of exploration in a Y-
maze (n=16 per genotype). Spontaneous alternations (SPA) are decreased in Oprm1
-/-
 
animals; alternate arm returns (AAR) and same arm returns (SAR) are increased. Data are 
presented as mean ± SEM. Solid stars: genotype effect, open stars: stimulus effect. One star 
p<0.05, two stars p<0.01, three stars p<0.001. See also Figure S1. 
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2004). We observed that male Oprm1
-/-
 mice displayed signs of aggressiveness in the three-
chamber test. We thus assessed the presence of aggressive behavior in these animals using the 
resident-intruder test. Animals were isolated 4 weeks before a naïve male was introduced in 
their home cage, daily for 4 days. In contrast with Oprm1
+/+
 controls, mutant animals engaged 
an increasing number of attacks towards the intruder mouse over sessions with shortening 
attack latency, together with increasing occurrence of ptosis episodes, a sign of 
aggressiveness in male mice (Defensor et al. 2012) (Figures 1c and S1d, Table S2). Moreover, 
mutant mice took significantly longer to leave their nest than controls during the first 3 
sessions, indicative of exacerbated defensive aggressiveness (Rawleigh and Kemble 1992) 
(Figure S1d). Thus aggressive behavior, a symptom often associated with ASDs, is increased 
in Oprm1
-/-
 animals. Finally, these mice revealed impaired ability to build a nest in the nesting 
behavior test (Figure 1d, Table S1). Together, these results indicate that adult Oprm1
-/-
 mice 
display abnormal social abilities, prolonging a recent report of social behavior deficits in 
juvenile animals (Cinque et al. 2012). 
Perseverative, stereotyped behaviors represent another major feature of ASDs, which 
we tested in mutant mice. When isolated in a novel standard cage, Oprm1
-/-
 mice displayed 
more frequent grooming, circling and head shakes but not rearing or burying, than Oprm1
+/+
 
animals (Figures 1e and S1e), suggestive of stereotyped behaviors. We also assessed 
flexibility and perseveration by performing a continuous spontaneous alternation task in a Y-
maze. Mutant animals showed decreased alternation, with increased frequency of alternate 
and same arm returns (Figure 1e). Increased stereotypic movements associated with reduced 
behavioral flexibility in Oprm1
-/-
 mice therefore completed autistic-like core symptoms in 
mutant mice. 
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Oprm1
-/-
 mice display multiple comorbid symptoms of autism 
The autistic syndrome also includes several comorbid symptoms with variable expression 
(reviewed in (Veenstra-VanderWeele and Blakely 2012). We first evaluated anxiety levels, as 
anxiety disorders are commonly associated to ASD. Previous studies have evidenced lower 
anxiety levels in mutant animals in the elevated plus-maze test (Filliol et al. 2000; Ide et al. 
2010). In the present work, we assessed anxiety-like behavior in additional paradigms, the 
marble burying test and the novelty-suppressed feeding test (NSF), which tax different aspects 
of anxiety. In the former, mutant animals buried more marbles than controls (Genotype: 
F1,16=6.5, p<0.05; Gender: F1,16<1, NS) (Figure 2a), demonstrating increased anxiety-induced 
stereotypies (Albelda and Joel 2012). In the NSF, a conflict test challenging 
approach/avoidance behavior (Aupperle and Paulus 2010), Oprm1
-/-
 mice took longer to start 
feeding in the arena center (Genotype: F1,16=49.9, p<0.001; Gender: F1,16<1, NS), and ate less 
chow when returned to their home cage (Genotype: F1,16=20.9, p<0.001; Gender: F1,16<1, NS) 
compared to controls (Figure 2b). Oprm1
-/-
 mice thus show increased conflict anxiety, which 
involves widespread neuronal activation (Aupperle and Paulus 2010). We measured such 
activation using Fos expression as a marker. When compared to Oprm1
+/+
, Oprm1
-/-
 mice 
displayed higher Fos expression in brain regions involved in the control of anxiety: CeA, CA1, 
LS, BNST, Cg2 and DR. In contrast, Fos labeling was lower in regions that modulate reward 
and motivation processes: VTA and LH (Figure 2c,d; Table S2). To correlate behavioral and 
Fos responses, we performed a PCA on NSF data (Figure 2e, left panel: variables’ space, right 
panel: subjects’ space). Interestingly, Fos expression in CeA correlated tightly with the 
latency to eat, an anxiety parameter, whereas Fos expression in VTA clustered with food 
intake, a motivation parameter, opposed along a first principal component (PC1, Table S3). 
Remarkably, projection in the subjects’ space (Figure 2e right) clearly dissociated Oprm1+/+ 
from Oprm1
-/-
 individual mice, demonstrating distinct patterns of behavioral responses and 

Figure 2. Oprm1
-/-
 mice display multiple secondary symptoms of autism.  
(a) Defensive anxiety is higher in mutant animals, hiding more marbles than controls in the 
marble-burying test (n=10 per genotype). (b) Conflict anxiety also is increased, as shown by 
longer feeding latencies in the novelty-suppressed feeding (NSF) test (n=10 per genotype). (c) 
and (d) Increased anxiety of Oprm1
-/-
 mice in NSF is associated with increased number of Fos 
positive (Fos+) nuclei in the central nucleus of the amygdala (CeA) and decreased Fos 
staining in the ventral tegmental area (VTA). (e) Principal component analysis on NSF data 
including behavioral (red dots) and Fos (grey dots) responses opposes food intake with 
latency to eat along the first principal component (PC1, 31.7% of variance). Fos expression in 
brain regions implicated in the regulation of anxiety-like behavior clusters with the latency 
parameter, and Fos-staining in neural circuits involved in the control of reward processes 
correlates with food intake (left panel: variables’ space). Oprm1+/+ and Oprm1-/- individual 
mice are dissociated in the subjects’ space (right panel). (f) and (g) Motor function is altered 
in mutant animals. Oprm1
-/-
 mice show impaired motor performance in the accelerating 
rotarod task (n=7 per genotype) and higher variability of pace size (sigma) in the footprint test 
(n=15-16 per genotype). (h) Sensitivity to pentylenetetrazole-induced seizures (n=8 per 
genotype) is increased in mice lacking the mu opioid receptor. Data are presented as mean ± 
SEM.  Genotype effect: one star p<0.05, two stars p<0.01, three stars p<0.001. See Figure S2 
for more tests and parameters, and complete list of abbreviations. 
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neuronal activation across the two mouse populations (Table S3). Together, the data indicate 
that under defensive (marble burying) or conflict (NSF) conditions, mice lacking mu opioid 
receptors display exacerbated anxiety coherent with the autistic phenotype.  
Besides anxiety, we used several tests to assess motor performance and coordination 
of Oprm1
-/-
 mice, as these are often altered in autistic children (Green et al. 2009; Johnson and 
Myers 2007). Mice were trained to run on an accelerating rotarod for three trials a day during 
four consecutive days. Oprm1
-/-
 mice stayed significantly shorter than control animals on the 
rod over sessions (Genotype: F1,10=42.5, p<0.001; Gender: F1,10<1, NS; Session: F3,30=6.8, 
p<0.01; Trial: F2,20=25.0, p<0.001; Genotype x Session: F3,30=5.2, p<0.01; Genotype x Trial: 
F2,20=5.2, p<0.05) (Figure 2f). Similarly, in the string test, these animals needed more time to 
grasp the string with a third paw (Genotype: F1,26=6.7, p<0.05; Gender: F1,26=1.5, NS), 
although their forelimb muscular strength was unchanged in the grip test (Figure S2b,c). 
Footprint analysis revealed an increased variability of pace length (sigma) in Oprm1
-/-
 mice 
(Genotype: F1,27=6.0, p<0.01; Gender: F1,27<1, NS) (Figures 2g and S2d). These data 
demonstrate impaired motor coordination in mutant animals. 
Finally, numerous autistic patients suffer from increased susceptibility to seizures 
(Robinson 2012). In agreement with earlier studies showing lowered seizure thresholds in 
response to several convulsant drugs in Oprm1
-/-
 mice (Grecksch et al. 2004; Jang et al. 2001), 
we found that pentylenetetrazole (37.5 and 50 mg/kg) induced more severe convulsions in 
mutants as compared to Oprm1
+/+
 animals (37.5 mg: H1,20=11.6, p<0.001; 50 mg: H1,20=10.0, 
p<0.01; no gender effect) (Figures 2h and S2e). 
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Behavioral deficits in Oprm1
-/-
 mice result from the null mutation rather than parental 
care  
We assessed the impact of parental rearing on observed behavioral deficits by performing 
time-mated cross-fostering of Oprm1
-/-
 mice and Oprm1
+/+
 controls (Peca et al. 2011). Cross-
fostered mutant animals showed impaired direct social interaction, stereotypic behavior and 
anxiety, but not nesting abilities, similar to those observed in Oprm1
-/-
 mice nurtured by 
mutant parents (Figure S3). These behaviors were not affected in Oprm1
+/+
 mice bred by 
mutant parents. 
 
Oprm1
-/-
 mice show modified transcription of several candidate genes for autism 
Multiple genes have been associated to the etiopathology of autism (Ecker et al. 2012a; Insel 
2010; State and Levitt 2011). We quantified transcription levels of a selection of these genes 
in Oprm1
+/+
 and Oprm1
-/- 
animals across four brain regions critical for emotional/cognitive 
processes and motor control: the PFC, CPu, NAc and CeA, using a qRT-PCR approach 
(Figure 3a; Figure S4a, Table S4). We detected changes in the expression of genes coding for 
the adhesion and scaffold proteins neuroligins (Nlgn1 and Nlgn2) and SHANK3 (Shank3). 
Transcriptional levels were also modified for the genes coding transporters of norepinephrine 
(NE, Slc6a2), dopamine (DA, slc6a3) and serotonin (5HT, slc6a4), as well as several 
receptors including beta3 subunit of GABAA receptors (Gababrb3) and 5HT2a serotonin and 
D2 dopamine receptors. The most dramatic changes in expression were observed for the 
genes coding the neuropeptides CRH and oxytocin. Finally, dysfunction of metabotropic 
glutamate receptors mGluR5 has received major attention as putative causative mechanism in 
fragile X syndrome and ASD (Carlson 2012). Expression of Grm5, coding these receptors, 
was not modified in Oprm1
-/- 
mice; however expression of Homer3, coding a key molecular 
interactor of mGluR5 receptors, was significantly down-regulated. Transcriptional 

Figure 3. Oprm1
-/-
 mice display transcriptional modifications and abnormal striatal 
synapses.  
(a) Transcription of multiple candidate genes for autism is modified in mutant animals across 
four brain regions (see details in Table S3). (b) Oprm1
-/-
 mice display abnormalities in the 
number of striatal symmetrical synapses (left panels, 120 frames per mouse at 40,000x 
magnification). Striatal asymmetrical synapses show reduced surface of postsynaptic densities 
(right panel). (c) Representative microphotographs (40,000x) illustrate morphology of striatal 
asymmetrical synapses in Oprm1
+/+
 and Oprm1
-/-
 mice. Scale bar: 200 nm. Asterisk: 
presynaptic element. (d) Clustering analysis of gene expression data classifies genes in four 
clusters (A-D). Cluster (D) gathers genes mostly involved in glutamatergic signaling that all 
show lowered mRNA levels in the caudate putamen and nucleus accumbens of Oprm1
-/-
 mice, 
among which Grm4 (framed), coding mGluR4 glutamate receptors, was detected only in these 
regions. Data in (a) and (b) are presented as mean ± SEM. Genotype effect: one star p<0.05, 
two stars p<0.01, three stars p<0.001. CeA: central nucleus of the amygdala, CPu: caudate 
putamen, NAc: nucleus accumbens, PFC: prefrontal cortex. See also Figure S4. 
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modifications observed in mutants were region-specific, prominent in the CPu and NAc. 
Inactivation of the mu opioid receptor gene, therefore, alters expression of several candidate 
genes for ASD, mainly in striatal regions. 
Mutant mice display abnormal striatal synapses, and modified transcription of GABA 
and glutamate signaling genes 
Abnormal basal ganglia function has been proposed as a key feature of autism (Di Martino et 
al. 2011; Kohls et al. 2012). In this study, deficient social behavior and motor clumsiness 
associated to stereotypic behavior in Oprm1
-/- 
animals point towards ventral and dorsal striatal 
dysfunction. We used electron microscopy to assess striatal synaptic morphology and 
observed an increased number of symmetrical synapses in both CPu and NAc of Oprm1
-/- 
mice (Genotype: F1,20=67.6, p<0.001; Structure: F1,20<1, NS), suggesting that inhibitory 
(GABAergic/glycinergic) local micro-circuitry is denser in these animals. The number of 
asymmetrical (glutamatergic) synapses was similar in mutants and controls; however, 
morphological analysis showed significant reduction in the area (CPu: F1,1505=81.3, p<0.001; 
NAc: F1,1209=19.1, p<0.001), but not length, of post-synaptic densities (PSDs; Figures 3b,c 
and S4b,c). These data strongly suggest that lack of mu opioid receptors alters the normal 
development of striatal synapses. 
Recent studies have revealed abnormal GABA and glutamate metabolism in 
individuals with autism, notably in striatal regions for the latter (Horder et al. 2013; Rojas et 
al. 2013). To test for altered signaling within these two major neurotransmitter systems, we 
performed comprehensive expression analysis of critical GABA and glutamate gene players 
across previous four brain regions (Table S4). We then identified groups of genes sharing 
similar expression profiles, using cluster analysis of all qRT-PCR data (Figures 3d and S4). 
Hierarchical clustering organized gene expression in five main clusters. Clusters (A) (B) and 
(C) grouped genes with high transcription levels in the NAc, CeA or CPu of mutant mice, 
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respectively. Sixteen genes in clusters (A) and (C) code GABAergic receptors/receptor 
subunits and transporters (Figure S4d), consistent with increased number of striatal 
symmetrical synapses in knockout animals. Cluster (D) retained our attention for gathering 
genes (zoomed in Figure 3d) with consistent lowered mRNA levels in the CPu and NAc of 
Oprm1
-/-
 mice, as compared to controls. Remarkably, fourteen genes in cluster (D) code 
glutamate receptors/receptor subunits and interacting proteins present in PSDs, further 
supporting electron microscopy data showing reduced PSD surface in mutants. Three major 
actors of the glutamate pathway, Gria2, Homer3 and Camk2a, showed low transcript levels 
across all tested brain regions, suggesting widespread alterations of glutamate signaling. 
Among genes coding metabotropic glutamate receptors, only Grm4 displayed statistically 
significant down-regulated expression and clustered in (D). Together, results suggest that mu 
opioid receptor gene knockout alters both GABA and glutamate signaling in the basal ganglia. 
 
The positive mGluR4 allosteric modulator VU0155041 alleviates autistic symptoms in 
Oprm1
-/-
 mice: comparison with the atypical antipsychotic risperidone 
Our qRT-PCR analysis revealed decreased transcription of Grm4, coding metabotropic 
glutamate receptors mGluR4, in the CPu and NAc of Oprm1
-/-
 animals (framed in Figure 3d). 
We reasoned that restoring mGluR4 activity in mutant mice using a positive allosteric 
modulator (PAM) may relieve behavioral deficits in these animals. We compared efficiency 
of a chronic treatment (7-17 days; Figure S5a) with VU0155041, a mGluR4 PAM (5 mg/kg), 
or risperidone (0.2 mg/kg) in improving autistic symptoms. Chronic treatment was chosen for 
better translational value, and to match published conditions of risperidone administration in 
mice (Penagarikano et al. 2011). We used risperidone as a reference, since atypical 
antipsychotics remain the only approved drugs for symptomatic treatment of ASDs. 
Risperidone acts at D2 and 5HT2a receptors and alleviates aggression and repetitive/self-

Figure 4. VU0155041, a positive allosteric modulator of mGluR4 glutamate receptors, 
and not the antipsychotic risperidone, restores initiation of social interaction in Oprm1
-/-
 
mice. (a) When a naïve wild-type social partner is used in the dyadic interaction test, chronic 
risperidone (0.2 mg/kg) restores normal frequency of nose and paw contacts as well as 
grooming episodes, but fails to increase the time spent in close contact, the duration of nose 
and paw contacts and the number of following episodes in mutant animals (n=14 per genotype 
and treatment). (b) Chronic treatment with VU0155041 (5 mg/kg) improves all these 
parameters except the number of following episodes, and increases the occurrence of paw 
contacts in controls (9-10 per genotype and treatment). (c) Using a paradigm in which each 
experimental mouse encounters a genotype and treatment-matched animal confirms the 
efficiency of VU0155041 to normalize or even facilitate social interaction in mutant mice, 
including the frequency of following episodes (n=7-8 per genotype and treatment). (d) 
Chronic VU0155041 administration normalizes deficient C-fos expression following social 
interaction in the NAc, MeA and VTA as well as deficient Egr1 expression in the VTA of 
Oprm
-/-
 mice. Data are presented as mean ± SEM. Open stars: treatment effect; black stars: 
genotype x treatment interaction (post-hoc: Newman-Keules test); grey stars: comparison 
with saline-treated Oprm1
+/+
 mice. One star p<0.05, two stars p<0.01, three stars p<0.001. 
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injurious behavior, but fails to significantly improve social abilities (Maher and Theodore 
2012). 
Risperidone and VU0155041 treatments demonstrated beneficial effects in the social 
interaction test by increasing the time spent in close contact and frequency of nose and paw 
contacts in mutants. Risperidone, however, failed to increase the duration of close contacts, 
while VU0155041 normalized or even increased this duration. Both treatments reduced 
grooming, especially after social contact (statistics in Tables S5 and S6), when treated animals 
interacted with a naïve WT conspecific (Figure 4a,b). Risperidone reduced activity of 
Oprm1
+/+
 control mice in our strain, as shown by decreased paw contacts and following in 
this test, confirmed by reduced horizontal activity and coherent with decreased striatal DA 
levels (Figure S5b,c; Table S7), in agreement with well described adverse sedative effects of 
atypical antipsychotics (Maher and Theodore 2012). In contrast, VU0155041 increased paw 
contacts and horizontal activity in both Oprm1
+/+
 and Oprm1
-/-
 lines (Figure S5d). To assess 
whether risperidone and VU0155041 treatments similarly restore initiation of social 
interaction despite opposing effects on activity, we performed the social interaction test with 
each experimental animal encountering a gender-, genotype- and treatment-matched 
conspecific (Figure S5g). No interactions could be observed between stimulus and test mice 
under risperidone, for both Oprm1
+/+
 and Oprm1
-/-
 lines, whereas VU0155041 fully restored 
social behavior in mutant mice with no effect in Oprm1
+/+
 animals (Figure S5h; statistics in 
Table S8). Finally, we assessed the effects of mGluR4 PAM treatment on neuronal activity 
induced by social exposure by measuring transcript levels of two immediate early genes, C-
fos and Egr1, following direct social interaction (second paradigm, Figure S5g). We used 
qRT-PCR for high detection sensitivity, and focused on brain regions involved in the control 
of reward processes and/or social behavior (PFC, NAc, VTA and MeA) (van Kerkhof et al. 
2013; Weathington et al. 2012). We confirmed that under these conditions chronic 

Figure 5. VU0155041 alleviates secondary symptoms of autism in Oprm1
-/-
 mice more 
efficiently than risperidone.  
(a) Both risperidone (left) and VU0155041 (right) treatments suppress motor stereotypies. (b) 
In the marble burying test, risperidone and VU0155041 normalize stereotyped burying in 
mutant mice; VU0155041, however, increases anxiety-induced burying in Oprm1
+/+
 mice. (c) 
Latencies to feed in the NSF do not significantly differ between Oprm1
+/+
 and Oprm1
-/-
 mice 
under risperidone treatment, while VU0155041 reverses the high latency to eat of Oprm1
-/-
 
mice to control levels. Food intake remains unchanged. Data are presented as mean ± SEM. 
Open stars: treatment effect; solid stars: genotype x treatment interaction (post-hoc: Newman-
Keules); One star p<0.05, two stars p<0.01, three stars p<0.001. See also Figure S5. 
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VU0155041 administration alleviates deficient social behavior in mutant mice (Figure 4c). 
Concomitantly, this treatment normalized the decreased expression of C-fos in the NAc, VTA 
and MeA of mutant animal after social interaction. Similarly, VU0155041 normalized or 
tended to normalize decreased expression of Egr1 in the VTA and MeA, respectively, and 
brought increased Egr1 transcription in the NAc back to wild-type levels in Oprm1
-/-
 mice 
(Figure 4d). These effects were not observed at the level of PFC. Thus mGluR4 PAM 
treatment, when administered to mutant mice, restored neuronal reactivity induced by social 
exposure in specific brain regions associated to reward and social behavior. 
Neither risperidone nor VU0155041 improved nesting scores in mutant animals 
(Figure S5e). In contrast, both suppressed stereotyped grooming and circling (Figures 5a and 
S5f) and normalized marble burying in Oprm1
-/-
 mice. VU0155041, however, increased 
stereotypic marble burying in Oprm1
+/+
 mice (Figure 5b). Risperidone had no detectable 
effect in the NSF; in contrast, VU0155041 restored a short latency to eat in mutant animals 
(Figure 5c; statistics in Tables S5 and S6). Compared to risperidone, the mGluR4 PAM was 
thus more efficient in alleviating social deficits and anxiety in Oprm1
-/-
 mice, with no 
depressive effect on general activity. To our knowledge, this is the first evidence that mGluR4 
represents a promising pharmacological target in the context of ASDs. 
 
Discussion 
Altogether, our data demonstrate that Oprm1 deletion is sufficient to produce a 
comprehensive spectrum of behavioral, neuroanatomical, biochemical and genetic landmarks 
of ASDs. Behaviorally, marked social interaction deficits in mutant animals extend previous 
findings of reduced maternal attachment and altered social and communication skills in these 
mice (Cinque et al. 2012; Moles et al. 2004; Wohr et al. 2011) to definitely demonstrate that 
mu opioid receptors are essential for establishing appropriate social behavior. Stereotyped and 
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perseverative behaviors detected in Oprm1
-/-
 mice further complete autistic-like core 
symptoms in these animals. In addition, mutant mice show multiple comorbid symptoms of 
ASD, including aggressiveness, exacerbated anxiety, motor clumsiness and increased 
susceptibility to seizures. Together with previously described impairments in spatial learning 
(Jamot et al. 2003), lowered nociceptive thresholds (Gaveriaux-Ruff and Kieffer 2002) and 
reduced gastrointestinal motility (Roy et al. 1998), mice lacking mu opioid receptors 
recapitulate the broadest autistic syndrome, including comorbid signs (Argyropoulos et al. 
2013; Veenstra-VanderWeele and Blakely 2012) but not gender bias (usually not tested in 
mouse models), ever described in preclinical research. Oprm1
-/-
 mice thus display remarkable 
face validity as an animal model of this pathology.  
Social interactions have been demonstrated to be intrinsically rewarding (Neuhaus et 
al. 2010; Trezza et al. 2010). Interestingly, imaging and psychophysical studies have provided 
evidence for reward dysfunction in autistic patients (Dichter et al. 2012; Kohls et al. 2012). 
These data are coherent with a recently emerged reward/motivation deficiency theory of 
autism (Chevallier et al. 2012; Dichter and Adolphs 2012) which proposes that disrupted 
social interest in ASD patients results from early deficits in their motivation for attending 
social stimuli, as well as enjoying and prolonging reciprocal social interactions. In humans, 
neural sensitivity to social rejection (Way et al. 2009) and social hedonic capacity (Troisi et al. 
2011) show significant association with a common variant (A118G) of Oprm1, and social 
acceptance activates mu opioid receptors in the NAc (Hsu et al. 2013), suggesting that mu 
opioid receptors are involved in social reward. Mu opioid receptors indeed play a critical role 
in mediating reward processes (Le Merrer et al. 2009). Interestingly, Oprm1
-/- 
mice show 
altered social place preference (Cinque et al. 2012) and blunted induction of C-fos and Egr1 
expression following social challenge in brain regions controlling reward processes and social 
recognition (NAc, VTA, MeA). These data suggest that social reward is compromised in 
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these animals, and thus substantiate the reward deficiency theory. Reduced mu opioid 
receptor function in early life, therefore, could represent a major molecular mechanism 
underlying reward and social behavior deficits in ASDs. Altered mu opioid receptor signaling 
would result either from invalidating mutations of Oprm1, as identified in several patients 
with ASD (SFARIgene
2.0
 database https://gene.sfari.org/autdb/Welcome.do), or from genetic 
or environmental factors that hamper mu opioid receptor activity. Alterations in other 
neurotransmitter systems may also contribute, and the profound decrease in Oxt gene 
expression in the NAc of Oprm1
-/-
 mice is most striking. Remarkably, oxytocin release in this 
region has been demonstrated to play a key role in social reward (Dolen et al. 2013). 
Moreover, this neuropeptide has been involved in the etiology of autism (Insel 2010), and 
oxytocin treatment demonstrated beneficial effects on social skills in ASD patients (Andari et 
al. 2010). Future studies will clarify mu opioid/oxytocin interactions and determine whether 
low oxytocin activity may result from deficient mu opioid receptor signaling. 
At cellular and molecular level, mutant mice also show most features characterizing 
ASDs in animal and clinical research. Oprm1
-/-
 mice exposed to a conflict situation showed 
increased and decreased neuronal activation in anxiety- and reward-associated brain structures, 
respectively, mimicking activation patterns observed in autistic patients (Dichter et al. 2012; 
Kohls et al. 2012). High 5HT and NE concentrations in the dorsal raphe of mutant mice 
(Table S5) parallel high blood levels for these two monoamines reported in autistic subjects 
(Lam et al. 2006). Altered expression of monoamine signaling genes (Slc6a2, Slc6a4, Htr2a, 
Maoa) is in line with findings of ASD behavioral features elicited by increased 
monoaminergic activity (Bortolato and Shih 2011). Mutant mice also showed altered 
expression for multiple genes associated to ASDs (Ecker et al. 2012a; Insel 2010; State and 
Levitt 2011). Finally, we collected anatomical and molecular evidence for altered 
glutamatergic neurotransmission, a feature common to several mouse models of ASD 
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(Carlson 2012; Peca et al. 2011; Won et al. 2012) and supported by genetic studies (Kelleher 
et al. 2012; Sato et al. 2012). Notably, expression of multiple genes coding major players of 
glutamate neurotransmission was down-regulated in striatal regions.  
We next tested therapeutic utility of Oprm1
-/-
 mice in the context of ASDs. 
Metabotropic glutamate receptors have received major attention as potential therapeutic 
targets for the treatment of ASDs (Carlson 2012). Transcriptome analysis identified 
expression of Grm4, coding metabotropic glutamate receptors mGluR4, as significantly 
down-regulated in the striatum of mutant animals. Grm4 shows a discrete pattern of mRNA 
expression in the brain, including striatal regions (Testa et al. 1994). High levels of 
presynaptic mGluR4 receptors are transported to nigral and pallidal output regions (Bradley et 
al. 1999; Corti et al. 2002) where they modulate GABA release. Activation of these receptors 
notably reduces GABAergic striatopallidal neurotransmission, with beneficial effects on 
dyskinesia/akinesia in animal models of Parkinson’s disease (Amalric et al. 2013). Moreover, 
PAMs of mGluR4 receptors decrease anxiety-like behavior in the marble burying and 
Volgel’s conflict tests (Duvoisin et al. 2011; Slawinska et al. 2013).We thus reasoned that 
restoring mGluR4 activity in mutant mice using such compound may ameliorate behavioral 
deficits in these animals. We found that chronic treatment with the PAM VU0155041 was 
more efficient than the antipsychotic risperidone in improving autistic-like symptoms in 
Oprm1
-/-
 mice, especially regarding social behavior, without sedative side effects. 
Interestingly, a chronic moderate dose of risperidone reduced striatal dopamine levels in our 
mice. Therefore, common beneficial effects of risperidone and VU0155041 on autistic-like 
deficits in our mouse model, despite their distinct molecular targets, may lie in their shared 
ability to moderate striatopallidal output, an intriguing novel hypothesis in the field. 
Remarkably, VU0155041 treatment in Oprm1
-/-
 mice normalized immediate early gene 
expression induced by social exposure in several brain regions processing reward and social 
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recognition, suggesting that facilitation of mGluR4 signaling was able to restore social reward 
in these animals. 
In conclusion, this study substantiates the notion that ASDs could be considered an 
extreme case of early-onset deficient reward processes, and proposes facilitation of mGluR4 
receptor activity as a promising novel therapeutic strategy. Future investigations will aim at 
better delineating the impact of mu opioid receptor deletion across brain regions and along the 
life span as a trigger for autistic syndrome, using local or time-controlled manipulations of 
gene expression. 
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